STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] OptiNose, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Schedule 13G/A filing by Nantahala Capital Management, LLC and two individuals reporting zero beneficial ownership in OptiNose, Inc. The filing states that as of June 30, 2025, Nantahala and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 0 shares of OptiNose common stock (CUSIP 68404V209), representing 0.00% of the class. The filing identifies Nantahala as an investment adviser organized in Massachusetts and lists the reporting persons' business address in New Canaan, Connecticut. Signatures include Nantahala through its Chief Compliance Officer and both individual reporting persons, dated August 14, 2025.

Positive
  • Complete disclosure of reporting persons, addresses, and CUSIP with signed certifications dated August 14, 2025
Negative
  • None.

Insights

TL;DR: The filing shows no economic stake by the reporting persons in OPTN, so there is no ownership-driven influence on the company.

The Schedule 13G/A discloses that Nantahala Capital Management and its named managers hold 0 shares (0.00%) of OptiNose as of June 30, 2025. For investors and analysts, this is a routine ownership disclosure indicating the filer is not a shareholder and therefore not an active investor exerting voting or dispositive influence. There are no financial metrics, transactions, or changes in ownership reported that would affect valuation or control.

TL;DR: Filing appears complete and compliant: reporting persons certified ordinary-course holdings and executed signatures.

The document classifies Nantahala as an investment adviser and includes the required certification that the securities, if any, are held in the ordinary course of business. All required identification fields are provided, including issuer address and CUSIP. The signed certifications dated August 14, 2025, satisfy typical Schedule 13G/A formalities. Because no shares are reported, there is no disclosure of group formation, material influence, or Section 13(d) activity to assess for risk.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:08/14/2025
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:08/14/2025
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:08/14/2025

FAQ

What does the Schedule 13G/A filed for OPTN disclose?

The filing discloses that Nantahala Capital Management, Wilmot B. Harkey, and Daniel Mack report 0 shares beneficially owned in OptiNose as of June 30, 2025, representing 0.00% of the class.

Who filed the Schedule 13G/A for OptiNose (OPTN)?

The filing was made by Nantahala Capital Management, LLC and reporting individuals Wilmot B. Harkey and Daniel Mack.

When is the ownership measurement date reported in the Schedule 13G/A?

The filing reports ownership as of June 30, 2025.

Does the Schedule 13G/A indicate Nantahala has control or a group with other holders?

No. The filing states 0 shares owned and lists Group-related items as not applicable or unchecked.

Were the required signatures provided on the Schedule 13G/A for OPTN?

Yes. The form is signed by Taki Vasilakis for Nantahala as Chief Compliance Officer and by both Wilmot B. Harkey and Daniel Mack on August 14, 2025.
Optinose

NASDAQ:OPTN

OPTN Rankings

OPTN Latest News

OPTN Latest SEC Filings

OPTN Stock Data

96.41M
9.47M
Pharmaceutical Preparation Manufacturing
Pharmaceutical Preparations
US
YARDLEY